1.Features of Histopathologic and radiographic findings in bisphosphonate-related osteonecrosis of jaw-Clinical review.
Joo Young OHE ; Yong Dae KWON ; Yeo Gab KIM ; Baek soo LEE ; Byoung Wook YOON ; Byoung Jun CHOI
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2008;34(5):550-554
Bisphosphonates (BPs) are a class of agent used to treat patient with osteoporosis or malignant bone metastases. BPs can be categorized into 2 groups: nitrogen-containing and non-nitrogen containing. Nitrogen-containing BPs are considered to have more toxicity. Despite their clinical benefits, bisphosphonate-related osteonecrosis of jaw(BRONJ) is a significant complication to patients receveing these drugs. Since the first description of BRONJ in 2003 by Marx, the number of reports on BRONJ has been rapidly increasing. BRONJ is considered as an emerging problem in oral & maxillofacial surgery. Generally, osteonecrosis in the maxilla is rare, however BRONJ is found both in the maxilla and the mandible. This is an important feature of BRONJ compared to common infectious osteomyelitis of the jaw. Growing number of case reports, suggest that bisphosphonate therapy may cause exposed, necrotic bone. BRONJ has simillar features compared to IORN (infected osteoradionecrosis). BRONJ has meaningful features established through the interestigation on histopathologic and radiographic findings. These features have an impact on treatment plan and prognosis. This presentation contemplates on features of histopathologic and radiographic findings in bisphosphonate-related osteonecrosis of the jaw.
Alendronate
;
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Diphosphonates
;
Humans
;
Jaw
;
Mandible
;
Maxilla
;
Neoplasm Metastasis
;
Osteomyelitis
;
Osteonecrosis
;
Osteoporosis
;
Prognosis
;
Surgery, Oral
2.An experimental study on the repair of the necrotic tubular bone with pedicled vascular periosteum grafting in rabbits.
Mu-zhang XIAO ; Xiao-yuan HUANG
Chinese Journal of Burns 2003;19(6):329-331
OBJECTIVETo investigate the mechanism of the repair of the necrotic tubular bone with pedicled vascular periosteum grafting in rabbits.
METHODSTwenty mature New Zealand rabbits aged 8 months were randomly divided into test and control groups by placebo-controlled protocol. A segment of radius measuring 1.2 cm in length with pedicled vascular periosteum of the rabbits in the test group was obtained from the middle distal part of the bone, and boiled for 30 minutes. The cooled bone was then re-grafted and wrapped with vascularized periosteum and immobilized, while those in the control group, no periosteal grafting was done. X-ray examinations of the bones were carried out at 2, 4, 6, 8 approximately 10 post operation weeks (POWs). Meanwhile 4-5 rabbits were sacrificed for the harvesting of the radius on both sides for histological examination.
RESULTSIt was revealed by X-ray and histological study that the periosteal hyperplasia could be observed 2-4 weeks after operation in the test group. The sign of union of the fracture and the formation and reconstitution of the trabeculae could be observed 6-8 weeks after operation. The reconstitution of reticulated bone, the formation of the lamellar bone and new haversian system could be observed during 8-10 POW. The structure of the new formed bones became more mature and the fracture healed at 12 POW. In contrast, there was no changes in the necrotic bones in the control group at 2 POW and no signs of fracture healing at 4-6 POW, and the defect of the bones could be observed at 8 POW. The necrotic bones were totally dissolved and absorbed, and the bone defects could be observed clearly filled with fibrotic tissues at 12 POW.
CONCLUSIONThe necrotic bones could be replaced by regeneration of new bone originated from the pedicled vascular periosteum, so that the necrotic tubular bones could be repaired. But the necrotic bones in the control group were eventually absorbed, resulting in bone defects.
Animals ; Burns ; surgery ; Female ; Male ; Osteonecrosis ; surgery ; Periosteum ; blood supply ; transplantation ; Rabbits
3.Avascular necrosis of a vertebral body.
Sheng-Li HUANG ; Wei SHI ; Xi-Jing HE
Chinese Journal of Traumatology 2009;12(2):125-128
Avascular necrosis of a vertebral body, a relatively uncommon entity, is caused by malignancy, infection, radiation, systemic steroid treatment, trauma, and the like.1 Vertebral osteonecrosis induced by trauma is called Kvmell's disease, because it was initially described by Hermann Kvmell of Germany in 1891.2 This paper reported a young female with posttraumatic vertebral osteonecrosis and analyzed the causes. She was treated by thoracoscopic surgery successfully.
Accidents, Traffic
;
Adolescent
;
Female
;
Humans
;
Kyphosis
;
etiology
;
Osteonecrosis
;
complications
;
surgery
;
Spinal Diseases
;
complications
;
surgery
;
Thoracoscopy
5.Partial Necrosis of the Mandibular Proximal Segment Following Transoral Vertical Ramus Osteotomy.
Somi KIM ; Sang Yoon KIM ; Gi Jung KIM ; Hwi Dong JUNG ; Young Soo JUNG
Maxillofacial Plastic and Reconstructive Surgery 2014;36(3):131-134
Transoral vertical ramus osteotomy (TOVRO) procedure can result in a variety of complications. Complications commonly reported include extensive bleeding due to major blood vessel injury, unpredictable fracture, postoperative infection, neurosensory deficit related Inferior alveolar nerve, insufficient osteosynthesis, and temporomandibular joint problem. The authors describe a case of partial necrosis of the mandibular proximal segment following TOVRO, a rarely reported complication. A 37-year-old otherwise healthy woman underwent Lefort l osteotomy and TOVRO to correct mandibular prognathism. Postoperatively, she developed pain and swelling in the right submandibular region and was found to have a partial necrosis of proximal segment.
Adult
;
Blood Vessels
;
Female
;
Hemorrhage
;
Humans
;
Mandibular Nerve
;
Necrosis*
;
Orthognathic Surgery
;
Osteonecrosis
;
Osteotomy*
;
Prognathism
;
Temporomandibular Joint
6.Clinical feature and treatment of bisphosphonate-related osteonecrosis of jaw about oral bisphosphonate administrated patients: case reports.
Woo Sung CHOI ; Hyun Joong YOON ; Sang Hwa LEE
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2010;36(6):508-514
Bisphosphonates are used effectively for many medical conditions, such as multiple myeloma, Paget's disease, osteoporosis, etc. However, recently, osteonecrosis of the jaw was observed in patients receiving long-term bisphosphonate therapy, including oral administration. This osteonecrosis is refractory, and complete recovery is not guaranteed despite a standard treatment protocol being established by many associations related to oral and maxillofacial surgery. The treatment outcome of oral bisphosphonate-related osteonecrosis of jaw (BRONJ) is reported with a review of the relevant literature.
Administration, Oral
;
Clinical Protocols
;
Diphosphonates
;
Humans
;
Jaw
;
Multiple Myeloma
;
Osteonecrosis
;
Osteoporosis
;
Surgery, Oral
;
Treatment Outcome
7.Visual and quantitative assessment of the effectiveness of non-vascularized bone grafting in osteonecrosis of the femoral head via CT-based radiomics and clinical data.
Xin LIU ; Hao CHEN ; Peng XUE ; Hongzhong XI ; Shuai HE ; Guangquan SUN ; Bin DU
Chinese Journal of Reparative and Reconstructive Surgery 2023;37(7):846-855
OBJECTIVE:
To investigate the value of CT-based radiomics and clinical data in predicting the efficacy of non-vascularized bone grafting (NVBG) in hip preservation, and to construct a visual, quantifiable, and effective method for decision-making of hip preservation.
METHODS:
Between June 2009 and June 2019, 153 patients (182 hips) with osteonecrosis of the femoral head (ONFH) who underwent NVBG for hip preservation were included, and the training and testing sets were divided in a 7∶3 ratio to define hip preservation success or failure according to the 3-year postoperative follow-up. The radiomic features of the region of interest in the CT images were extracted, and the radiomics-scores were calculated by the linear weighting and coefficients of the radiomic features after dimensionality reduction. The clinical predictors were screened using univariate and multivariate Cox regression analysis. The radiomics model, clinical model, and clinical-radiomics (C-R) model were constructed respectively. Their predictive performance for the efficacy of hip preservation was compared in the training and testing sets, with evaluation indexes including area under the curve, C-Index, sensitivity, specificity, and calibration curve, etc. The best model was visualised using nomogram, and its clinical utility was assessed by decision curves.
RESULTS:
At the 3-year postoperative follow-up, the cumulative survival rate of hip preservation was 70.33%. Continued exposure to risk factors postoperative and Japanese Investigation Committee (JIC) staging were clinical predictors of the efficacy of hip preservation, and 13 radiomic features derived from least absolute shrinkage and selection operator downscaling were used to calculate Rad-scores. The C-R model outperformed both the clinical and radiomics models in predicting the efficacy of hip preservation 1, 2, 3 years postoperative in both the training and testing sets ( P<0.05), with good agreement between the predicted and observed values. A nomogram constructed based on the C-R model showed that patients with lower Rad-scores, no further postoperative exposure to risk factors, and B or C1 types of JIC staging had a higher probability of femoral survival at 1, 2, 3 years postoperatively. The decision curve analysis showed that the C-R model had a higher total net benefit than both the clinical and radiomics models with a single predictor, and it could bring more net benefit to patients within a larger probability threshold.
CONCLUSION
The prediction model and nomogram constructed by CT-based radiomics combined with clinical data is a visual, quantifiable, and effective method for decision-making of hip preservation, which can predict the efficacy of NVBG before surgery and has a high value of clinical application.
Humans
;
Bone Transplantation
;
Femur Head/surgery*
;
Femur
;
Osteonecrosis
;
Tomography, X-Ray Computed
;
Retrospective Studies
8.Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.
Jeong Keun LEE ; Kyung Wook KIM ; Jin Young CHOI ; Seong Yong MOON ; Su Gwan KIM ; Chul Hwan KIM ; Hyeon Min KIM ; Yong Dae KWON ; Yong Deok KIM ; Dong Keun LEE ; Seung Ki MIN ; In Sook PARK ; Young Wook PARK ; Min Suk KOOK ; Hong Ju PARK ; Jin A BAEK ; Jun Woo PARK ; Tae Geon KWON
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2013;39(1):9-13
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0+/-10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Administration, Intravenous
;
Alendronate
;
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Data Collection
;
Diphosphonates
;
Etidronic Acid
;
Humans
;
Incidence
;
Jaw
;
Korea
;
Osteonecrosis
;
Schools, Dental
;
Schools, Medical
;
Surgery, Oral
;
Risedronate Sodium
9.Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.
Jeong Keun LEE ; Kyung Wook KIM ; Jin Young CHOI ; Seong Yong MOON ; Su Gwan KIM ; Chul Hwan KIM ; Hyeon Min KIM ; Yong Dae KWON ; Yong Deok KIM ; Dong Keun LEE ; Seung Ki MIN ; In Sook PARK ; Young Wook PARK ; Min Suk KOOK ; Hong Ju PARK ; Jin A BAEK ; Jun Woo PARK ; Tae Geon KWON
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2013;39(1):9-13
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0+/-10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Administration, Intravenous
;
Alendronate
;
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Data Collection
;
Diphosphonates
;
Etidronic Acid
;
Humans
;
Incidence
;
Jaw
;
Korea
;
Osteonecrosis
;
Schools, Dental
;
Schools, Medical
;
Surgery, Oral
;
Risedronate Sodium
10.Bisphosphonate, is it an emerging risk factor in oral surgery?
Yong Dae KWON ; Byung Wook YOON ; Christian WALTER
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons 2007;29(5):456-462
osteonecrosis of the jaw (BRONJ) in 2002, the number of report on the disease has rapidly been increasing. Now, BRONJ is considered as a new entity, which is emerging problem in oral and maxillofacial surgery. Bisphosphonates (BPs) can be categorized into 2 groups: nitrogen-containing and non-nitrogen containing, and nitrogen-containing BPs are considered to have more efficacy and toxicity possibly. It is unusual for osteonecrosis to occur in the maxilla but BRONJ is found in both the mandible and the maxilla, which is one of the special features of BRONJ compared with common infectious osteomyelitis of the jaws. Intravenous BPs are usually more likely to cause BRONJ than oral BPs which are frequently prescribed for osteoporosis and osteopenia. Nonetheless, the use of intravenous BPs cannot be prevented because of systemic condition of the patients. Although it is rare that oral BPs cause BRONJ in osteoporosis/osteopenia patients, we should be aware of BRONJ since the population of the patients is exceedingly increasing with the prolonging of life expectancy. So, we'd like to enlighten upon the problems and solutions of BRONJ.]]>
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Bone Diseases, Metabolic
;
Diphosphonates
;
Humans
;
Jaw
;
Life Expectancy
;
Mandible
;
Maxilla
;
Osteomyelitis
;
Osteonecrosis
;
Osteoporosis
;
Risk Factors
;
Surgery, Oral